

#### UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/525,797	03/15/2000	Athanasius A Anagnostou	5218-39B	9917	
20792	7590 08/05/2002				
MYERS BI	GEL SIBLEY & SAJ	EXAMINER			
PO BOX 37428 RALEIGH, NC 27627			UNGAR, SUSAN NMN		
			ART UNIT	PAPER NUMBER	
			1642	0	
			DATE MAILED: 08/05/2002	9	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 09/525,797 Applicant(s)

Anagnostou et al

Examiner

Ungar

Art Unit 1642



	The MAILING DATE of this communication appears	on the cover s	heet with	the correspondence address			
	for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the							
mailing	date of this communication.						
- If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6 ne application to bec	3) MONTHS from ABANDO	om the meiling date of this communication. NED (35 U.S.C. § 133).			
Status							
1) X	Responsive to communication(s) filed on Jun 26, 2	002		•			
2a) 💢	This action is <b>FINAL</b> . 2b) $\square$ This act	ion is non-fina	al.				
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under Ex pair						
Disposi	tion of Claims						
4) 💢	Claim(s) 12-15 and 17-25			is/are pending in the application.			
4	la) Of the above, claim(s)			is/are withdrawn from consideration.			
5) 🗆	Claim(s)			is/are allowed.			
6) 💢	Claim(s) 12-15 and 17-25						
7) 🗆	Claim(s)			is/are objected to.			
8) 🗆	Claims	ar	e subject	to restriction and/or election requirement.			
Applica	tion Papers						
9) 🗆	The specification is objected to by the Examiner.				,		
10)	The drawing(s) filed on is/are	a) 🗆 accept	ed or b)	$\square$ objected to by the Examiner.			
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	The proposed drawing correction filed on	i:	s: a)□ a	pproved b) $\square$ disapproved by the Examine	er.		
	If approved, corrected drawings are required in reply t						
12)	The oath or declaration is objected to by the Exami	ner.					
Priority	under 35 U.S.C. §§ 119 and 120						
13)□	Acknowledgement is made of a claim for foreign pr	riority under 3	5 U.S.C.	§ 119(a)-(d) or (f).			
a) 🗆	☐ All b)☐ Some* c)☐ None of:						
	1. $\square$ Certified copies of the priority documents have	e been receiv	ed.				
	2. $\square$ Certified copies of the priority documents have	e been receiv	ed in App	lication No			
	3. Copies of the certified copies of the priority de application from the International Bure	au (PCT Rule	17.2(a)).	•			
	ee the attached detailed Office action for a list of the						
14) ∐	Acknowledgement is made of a claim for domestic						
	The translation of the foreign language provisiona						
15)∟ ^********	Acknowledgement is made of a claim for domestic	priority under	30 0.5.0	J. 33 120 and/or 121.			
Attachm 1) No	ent(s) tice of References Cited (PTO-892)	4) Interview S	ummarv (PTO	-413) Paper No(s).			
_	tice of Draftsperson's Patent Drawing Review (PTO-948)		•	Application (PTO-152)			
_	3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)						

Serial No: 09525797

Art Unit: 1642

1. The Amendment filed June 26, 2002 (Paper No. 8) in response to the Office Action of March 20, 2002 (Paper No. 7) is acknowledged and has been entered. Previously pending claims 12-15 and 17-25 are currently being examined.

- 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 3. The following rejections are maintained:

#### Claim Rejections - 35 USC § 112

5. Claims 12-15 and 17-25 remain rejected under 35 USC 112, first paragraph for the reasons previously set forth in Paper No. 7, Section 5, pages 3-10.

Applicant argues that one of skill in the art would know how to practice the invention. The argument has been considered but has not been found persuasive for the reasons previously set forth. Further, it is noted that Applicant has not addressed the critical issues drawn to the biphasic effects of EPO and dosage, the contradictory evidence of the Anagnostou Declaration. Applicant's arguments have not been found persuasive and the rejection is maintained.

### Claim Rejections - 35 USC § 102

6. Claims 12-15 and 21, 23-25 remain rejected under 35 USC 102(b) for the reasons previously set forth in Paper No. 7, Section 9, pages 11-12.

Applicant argues that the treatment disclosed by Platanias et al is not the same as that claimed. The argument has been considered but has not been found persuasive because the method of the prior art comprises the same method steps as claimed in the instant invention, to the same population, thus the claimed method is anticipated because the method will inherently treat the solid vascularized tumor.

Serial No: 09525797 Page 3

Art Unit: 1642

Applicant's arguments have not been found persuasive and the rejection is maintained.

#### Claim Rejections - 35 USC § 103

7. Claims 12-15 and 17-25 remain rejected under 35 USC 102(b) for the reasons previously set forth in Paper No. 7, Section 9, pages 11-12.

Applicant argues that the references either alone or in combination fail to suggest all of the claim recitations of the present invention. The argument has been considered but has not been found persuasive for the reasons set forth above and further because the art clearly teaches that administration of intravenous cisplatin is a conventional protocol in the treatment of solid tumors. Applicant's arguments have not been found persuasive and the rejection is maintained.

- 8. All other objections and rejections recited in Paper No. 7 are withdrawn.
- 9. No claims allowed.
- 10. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE

Serial No: 09525797

Art Unit: 1642

# STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Ungar, PhD whose telephone number is (703) 305-2181. The examiner can normally be reached on Monday through Friday from 7:30am to 4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached at (703) 308-3995. The fax phone number for this Art Unit is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Effective, February 7, 1998, the Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1642.

Susan Ungar

**Primary Patent Examiner** 

August 1, 2002